Home » About us » Corporate highlights

Corporate highlights

Corporate highlights

  • Privately-held Montreal-based biotechnology company
  • Engaged in the discovery and development of therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets
  • Currently having three pre-clinical programs with two INDs expected within the next 2 – 8 months
  • Extensive portfolio of highly-specific, novel and clinically-relevant targets using the proprietary STAR technology
  • Exploiting a powerful a proprietary target discovery technology with the potential to expand pipeline
  • Established strategic partnerships to access mAb generation, humanization, antibody drug conjugates, and CHO production technologies
  • Seasoned management and multi-disciplinary discovery and early-stage development team
  • Unencumbered pipeline with the potential for selected strategic partnerships on therapeutic mAbs